Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1/2 4Phase 3 3Phase NA 1Phase 1 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Plasma cell 1

Conditions

Prostatic Neoplasms 2Multiple Myeloma 1Bone Metastases 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × radium Ra 223 dichloride × Clear all
NCT03317392 2026-05-20

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
132 enrolled 22 charts
Genitourinary

Prostatic Neoplasms

NCT02928029 2020-02-26

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

Bayer

Phase 1/2 Terminated
7 enrolled 9 charts
Plasma cell

Multiple Myeloma

NCT01934790 2018-03-26

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Bayer

Phase 1/2 Completed
45 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

NCT01106352 2017-01-04

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Bayer

Phase 1/2 Completed
70 enrolled 26 charts
Genitourinary

Bone Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡